Sarah J Valk

TL;DR: To continually assess, as more evidence becomes available, whether convalescent plasma or hyperimmune immunoglobulin transfusion is effective and safe in treatment of people with COVID-19, a first living update of this review is published.

TL;DR: Assessing whether convalescent plasma or hyperimmune immunoglobulin transfusion is effective and safe in the treatment of people with COVID-19 found all-cause mortality at hospital discharge, improvement of clinical symptoms, grade 3 and 4 adverse events, and serious adverse events were reported.

TL;DR: This is a protocol for a Cochrane Review to assess whether SARS-CoV-2-neutralising mAbs are effective and safe for treating patients with COVID-19 in comparison to an active comparator, placebo or no intervention.

TL;DR: This protocol is a protocol for a Cochrane Review (intervention) to assess the effectiveness and safety of SARS-CoV-2-neutralising mAbs, including mAb fragments, and to maintain the currency of the evidence using a living systematic review approach.

TL;DR: Convalescent plasma may reduce mortality in patients with viral respiratory diseases, and is being investigated as a potential therapy for coronavirus disease 2019 (COVID-19) as mentioned in this paper .